RSPO3 and neoplasm: Our findings demonstrate that targeting RSPO3 promoter DNA methylation using sg-RSPO3-dCas9DNMT3a leads to a decrease in RSPO3 expression and promotes CCA progression. Aberrant expression of methylcytosine dioxygenase TET1 is involved in epigenetic reprogramming and tumor progression [35].